Episode 170 - January 23, 2026

The Biotech Hangout podcast centers on the state of the biotech industry, exploring factors driving optimism and potential challenges. Tim Opler's bullish outlook, supported by positive fund flows and underappreciated pricing dynamics, sets the stage. Concerns arise around FDA unpredictability, potential reversals in drug pricing policies, and the impact of China on the U.S. biotech industry. The conversation highlights the opening IPO market, the quality of companies going public, and the importance of solid, de-risked issues. Discussions also cover GSK's acquisition of RAPT Therapeutics, BMS's deal with Janux, policy issues such as NIH funding, PBM reform, U.S. withdrawal from the WHO, and FDA guidance on minimal residual disease. The podcast further examines companies in the atopic dermatitis space, and the historical context and future potential of women's health.